Abstract
A 41-year-old male visited our hospital with proteinuria and hearing loss. The patient is Japanese, had never experienced pain attacks in the extremities, and sweats normally. He did not present with chest pains and palpitations and often had diarrhea without abdominal pain. Proteinuria was diagnosed when he was 25 years old, and he was then diagnosed with chronic nephritis. At 30 years of age, he experienced recurrent sudden-onset deafness, sometimes with tinnitus. He had hypertension, hypercholesterolemia, and hyperuricemia. His electrocardiogram revealed arrhythmia, and he had a panic disorder. He gave up smoking when he was 30 years old. His mother had cardiac involvement with Fabry disease but no history of kidney diseases. She also had a c.465 T > A (amino acid: D155E) heterozygous mutation in α-galactosidase A of white blood cells. Physical examination revealed his body mass index was 22.5 kg/m2 and had regular heartbeats, but no hepatosplenomegaly, no angiokeratoma, no rash, and no any neurological sign. In his blood counts, there were normal white blood cells and platelet but no anemia. His serum creatinine 0.97 mg/dL (normal; 0.65–1.07), estimated glomerular filtration rate (eGFR) 69 mL/min/1.73 m2 (normal; >90) and cystatin C 0.90 mg/L (normal; 0.63–0.95), LDL-cholesterol 98 mg/dL (65–139), and triglyceride 188 mg/dL (normal; 40–149) were almost normal, but brain natriuretic peptide 55.3 pg/mL(normal; <18.5) was slightly elevated. He exhibited proteinuria (3+) and quantitative urine protein/creatinine ratio 3.8 g/g Cr (normal; <0.3) but not hematuria. Serum α-galactosidase A activity 2.82 nmol/hr/mg protein in his white blood cells was extremely low (normal control: 155.85–222.59). Thin-layer chromatography of his urinary lipids indicated globotriaosylceramide (Gb3) positive (Fig. 4.1). Gene analysis identified c.465 T > A (amino acid: D155E) hemizygous mutation in α-galactosidase A of his white blood cells.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Ashe KM, Budman E, Bangari D et al (2015) Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease. Mol Med 21:389–399
Brady RO, Tallman JF, Johnson WG et al (1973) Replacement therapy for inherited enzyme deficiency-use of purified Ceramidetrihexosidase in Fabry’s disease. N Engl J Med 289:9–14
Desnick RJ, Ioannou YA, Eng CM (2017) 150: α-Galactosidase a deficiency: Fabry disease in the online metabolic and molecular bases of inherited disease. http://ommbid.mhmedical.com/content.aspx?sectionid=62644837&bookid=971&Resultclick=2
Eng CM, Fletcher J, Wilcox WR et al (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry registry. J Inherit Metab Dis 30:184–192
Germain DP, Hughes DA, Nicholls K et al (2016) Treatment of Fabry’s disease with the pharmacologic chaperone Migalastat. New Engl J Med 375:545–555
Gubler MC, Lenoir G, Grunfeld JP et al (1978) Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int 13(3):223–235
Kanai T, Yamagata T, Ito T et al (2011) Foot process effacement with normal urinalysis in classic Fabry disease. JIMD Rep 1:39–42
Kobayashi M, Ohashi T, Fukuda T et al (2012) No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene. Mol Genet Metab 107(4):711–715
Ohashi T, Iizuka S, Ida H et al (2008) Reduced a-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol Genet Metab 94:313–318
Pacienza N, Yoshimitsu M, Mizue N et al (2012) Lentivector transduction improves outcomes over transplantation of human HSCs alone in NOD/SCID/Fabry mice. Mol Ther 20(7):1454–1461
Press release (April 8th, 2016) Phase I Gene Therapy Study for Fabry Disease, University of Calgary, Canada
Schiffmann R, Ries M, Timmons M et al (2006) Long-term therapy with agalsidase alpha for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345–354
Schuller Y, Linthorst GE, Hollak CEM et al (2016) Pain management strategies for neuropathic pain in Fabry disease – a systematic review. BMC Neurol 16:25
Wilcox WR, Banikazemi M, Guffon N et al (2004) International Fabry disease study group, long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74
Wilcox WR, Linthorst GE, Germain DP et al (2012) Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry registry. Mol Genet Metab 105:443–449
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Sakurai, K., Ohashi, T. (2019). Fabry Disease. In: Oohashi, T., Tsukahara, H., Ramirez, F., Barber, C., Otsuka, F. (eds) Human Pathobiochemistry. Springer, Singapore. https://doi.org/10.1007/978-981-13-2977-7_4
Download citation
DOI: https://doi.org/10.1007/978-981-13-2977-7_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-2976-0
Online ISBN: 978-981-13-2977-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)